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OBJECTIVES: Pancreatitis is the most common and serious complication of diagnostic and therapeutic ERCP. The
aim of this study is to examine the potential patient- and procedure-related risk factors for
post-ERCP pancreatitis in a prospective multicenter study.
METHODS: A 160-variable database was prospectively collected by a defined protocol on patients undergoing
diagnostic or therapeutic ERCP at 15 centers in the Midwest Pancreaticobiliary Group and
participating in a randomized controlled study evaluating whether prophylactic corticosteroids will
reduce the incidence of post-ERCP pancreatitis. Data were collected prior to the procedure, at the
time of procedure, and 24–72 h after discharge. Post-ERCP pancreatitis was diagnosed and its
severity graded according to consensus criteria.
RESULTS: Of the 1,115 patients enrolled, diagnostic ERCP with or without sphincter of Oddi manometry (SOM)
was performed in 536 (48.1%) and therapeutic ERCP in 579 (51.9%). Suspected sphincter of Oddi
dysfunction (SOD) was the indication for the ERCP in 378 patients (33.9%). Pancreatitis developed
in 168 patients (15.1%) and was graded mild in 112 (10%), moderate in 45 (4%), and severe in
11(1%). There was no difference in the incidence of pancreatitis or the frequency of investigated
potential pancreatitis risk factors between the corticosteroid and placebo groups. By univariate
analysis, the incidence of post-ERCP pancreatitis was significantly higher in 19 of 30 investigated
variables. In the multivariate risk model, significant risk factors with adjusted odds ratios (OR) were:
minor papilla sphincterotomy (OR: 3.8), suspected SOD (OR: 2.6), history of post-ERCP pancreatitis
(OR: 2.0), age <60 yr (OR: 1.6), ≥2 contrast injections into the pancreatic duct (OR: 1.5), and
trainee involvement (OR: 1.5). Female gender, history of recurrent idiopathic pancreatitis, pancreas
divisum, SOM, difficult cannulation, and major papilla sphincterotomy (either biliary or pancreatic)
were not multivariate risk factors for post-ERCP pancreatitis.
CONCLUSION: This study emphasizes the role of patient factors (age, SOD, prior history of post-ERCP pancreatitis)
and technical factors (number of PD injections, minor papilla sphincterotomy, and operator
experience) as the determining high-risk predictors for post-ERCP pancreatitis.
(Am J Gastroenterol 2006;101:139–147)
INTRODUCTION
Pancreatitis is the most common and feared complication
of ERCP, occurring in up to 30–40% of high-risk patients
(1–3). It is associated with substantial morbidity and occa-
sional mortality. There have been ongoing efforts to minimize
the incidence and severity of post-ERCP pancreatitis. Precise
identification of risk factors for post-ERCP pancreatitis is es-
sential to recognize high-risk cases in which ERCP should
be avoided if possible, or in which protective endoscopic
or pharmacologic interventions should be considered (2, 4).
The mechanisms that lead to post-ERCP pancreatitis are not
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fully understood but believed to be multifactorial (mechan-
ical, chemical, hydrostatic, enzymatic, microbiologic, and
thermal), and the triggering event is thought to cause pre-
mature intracellular activation of proteolytic enzymes within
acinar cells resulting in cellular injury and autodigestion of
pancreatic tissue (1, 5).
A number of specific risk factors, acting independently or
in concert, have been proposed as predictors of post-ERCP
pancreatitis. These include both patient- and procedure-
related factors. However, the reported risk factors vary widely
from study to study. These discrepancies may be attributable
to heterogeneous patient populations, differing levels of en-
doscopic expertise, varying cannulation techniques, and dis-
parate definition of post-ERCP pancreatitis. More important,
the use of univariate analysis to identify risk factors for post-
ERCP pancreatitis may produce misleading results because
of inability to sort out confounding variables (6–10). Recent
studies have used multivariate analysis as a tool to identify
and quantify the effect of multiple potentially confounding
risk factors (11–20).
The aim of this study was to use multivariate analysis and
examine the independent risk factors for post-ERCP pancre-
atitis in a group of patients who were prospectively random-
ized to receive prophylactic corticosteroids or placebo in a
double-blinded, multicenter, controlled clinical trial.
MATERIALS AND METHODS
Physicians from 15 participating endoscopic centers affili-
ated with the Midwest Pancreaticobiliary Group conducted
a randomized, prospective, placebo-controlled study to eval-
uate whether prophylactic administration of corticosteroids
reduces the risk and severity of post-ERCP pancreatitis. Data
were prospectively collected to determine the patient- and
procedure-related risk factors for post-ERCP pancreatitis.
The research proposal was approved by the institutional re-
view boards at all participating centers.
Patients
Patients were recruited serially as they presented for diag-
nostic or therapeutic ERCP. Patients were excluded from the
study for any of the following reasons: (1) age less than
18 yr, (2) pregnancy, (3) mental disability, (4) incarcera-
tion, (5) active pancreatitis before procedure, (6) allergy to
corticosteroids, (7) actual treatment with corticosteroids, (8)
active tuberculosis, (9) uncontrolled diabetes, (10) contrast
allergy, (11) known hepatitis B, (12) active bacteremia or
septicemia, (13) planned biliary stent removal or exchange
without planned pancreatogram, or (14) need for emergent
ERCP within 12 h.
Study Protocol
After obtaining informed consent, enrolled patients were ran-
domized to receive either prednisone, 40 mg by mouth, 15
h (±3 h) and 3 h (±1 h) before ERCP, or a placebo (simi-
lar pill without the active drug) given at similar time inter-
vals. Randomization was accomplished in a blinded fash-
ion by pharmacy staff. In sequence, concealed envelops
with active drug or placebo were dispensed. Baseline values
for biochemical tests of liver function, amylase and lipase,
and a complete blood count (CBC) were determined before
the procedure. ERCP was performed by using the standard
high-osmolality ionic-contrast agent diatrizoate meglumine
(Hypaque, Winthrop Pharmaceuticals, New York, NY). A
CBC and serum amylase and lipase levels were obtained at
2–4 h after the ERCP was completed. Patients were prospec-
tively evaluated for the development of post-ERCP pan-
creatitis. Admission of an outpatient or prolongation of
current hospitalization was at the discretion of the man-
aging physician. Patients discharged on the day the ERCP
was performed were contacted by telephone during the 24–
72 h following the procedure to assess their clinical con-
dition and evaluate for the development of postprocedure
pancreatitis.
Definitions
Suspected sphincter of Oddi dysfunction (SOD) referred to
the pre-ERCP suspicion of a functional or structural abnor-
mality of the sphincter of Oddi, independent of any manomet-
ric findings, thought to be the cause of recurrent abdominal
pain or pancreatitis. Cannulation difficulty was determined
on the basis of the number of attempts on the papilla with a
cannulation instrument (both common bile duct and pancre-
atic duct). Cannulation was judged easy when one to eight
attempts took place and moderate/difficult when more than
eight occurred. The number of pancreatic duct injections was
the total number of times any volume of contrast was injected
into the pancreatic duct. Acinarization was defined as any flu-
oroscopically observed focal or diffuse pancreatic parenchy-
mal blush of contrast. Bile duct diameter was the measured
maximal duct diameter within 2 cm of the papilla adjusted for
radiographic magnification. Chronic pancreatitis was defined
as the presence of mild, moderate, or severe pancreatographic
abnormalities according to Cambridge criteria (21).
The definition of pancreatitis and the grading of its severity
were based on consensus criteria (3). Post-ERCP pancreatitis
was diagnosed when new-onset or increased abdominal pain
lasted for more than 24 h, caused an unplanned admission of
an outpatient for more than one night or prolonged a planned
hospitalization of an inpatient, and was associated with an
increase in serum amylase level of at least three times greater
than the normal upper limit at approximately 18 h (the next
morning) after the procedure. The severity of the pancreati-
tis was graded mild when hospitalization lasted 2–3 days,
moderate when 4–10 days, and severe when hospitalization
was prolonged for more than 10 days or any of the follow-
ing occurred: hemorrhagic pancreatitis, pancreatic necrosis,
pancreatic pseudocyst, or a need for percutaneous drainage
or surgery.
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Data Management
Demographic, procedure, and follow-up data were prospec-
tively collected at the time of the procedure, before, and 24–72
h after discharge, and entered into a 160-variable database.
The database was developed using specific software (Foxpro,
Microsoft Corp., Seattle, WA) with screen entry and built-in
edit checks to maintain the quality of the data. The clinical
centers were asked to send copies of the data form to the
coordinating center. The data were then entered by a nurse
coordinator and checked by a second coordinator.
Statistical Analysis
The primary outcome analyzed was development of post-
ERCP pancreatitis. Risk factors for pancreatitis were assessed
using univariate analysis with χ2 test for categorical variables
and simple logistic regression for continuous variables. Vari-
ables with a p value less than 0.2 in the univariate analysis
were all included in a forward stepwise multiple logistic re-
gression model to identify the independent risk factors for
pancreatitis. Goodness-of-fit for the final multivariate model
was assessed by the 2-log likelihood criterion. Statistical anal-
yses were performed using the statistical software package
SAS version 8.2 (SAS Institute, Cary, NC).
RESULTS
A total of 1,115 patients (396 men, 719 women; mean age
51.2 [16.7] yr) were enrolled into the study (Table 1). Five
hundred fifty-five patients were randomized to the prednisone
group and 560 to the placebo group. The rates of post-ERCP
pancreatitis in those patients receiving oral prednisone and
those receiving placebo have been reported previously (22).
Because the frequency of post-ERCP pancreatitis (16.6% re-
ceiving prednisone vs 13.6% in the placebo group, p = 0.19)
and the risk factors for pancreatitis were similar for both
groups, the data presented here will be combined treatment
and placebo groups unless otherwise stated.
Three hundred and seventy-eight patients (33.9%) were
evaluated for suspected SOD. A prior history of post-
ERCP pancreatitis was noted in 81 patients (7.3%). Diag-
nostic ERCP with or without sphincter of Oddi manome-
try (SOM) was performed in 536 patients (48.1%), while
579 patients (51.9%) underwent therapeutic procedures. En-
doscopic sphincterotomies were performed in 577 patients
Table 1. Patient Characteristics
Number of patients 1115
% female 64.5%
Mean age 51.2
Number older than 60 yr old 362 (32.5%)
Mean BMI 26.8 kg/m2
Prior pancreatitis 433 (38.8%)
Suspected SOD 378 (33.9%)
Chronic pancreatitis 192 (16.1%)
BMI = body mass index; SOD = sphincter of Oddi dysfunction.
(51.7%); sphincterotomies were biliary alone in 381 patients
(34.2%), pancreatic alone (major and/or minor papilla) in 126
patients (11.3%), and dual pancreaticobiliary in 70 patients
(6.3%). Manometry was performed in 395 patients (35.4%);
SOM was biliary alone in 98 patients (8.8%), pancreatic alone
in 47 (4.2%), and both biliary and pancreatic in 250 (22.4%).
Precut sphincterotomy was performed in 103 patients (9.2%).
Pancreas divisum was found in 123 patients (11.0%) and
minor papilla sphincterotomy was performed in 50 (4.5%).
Chronic pancreatitis was found in 192 patients (17.2%).
Post-ERCP pancreatitis occurred in 168 patients (15.1%).
It was graded as mild in 112 patients (10%), moderate in 45
(4%), and severe in 11 (1%). Pancreatitis occurred after 63
(11.8%) of 536 ERCPs that were diagnostic alone and 105
(18.1%) of 579 procedures that were therapeutic.
Univariate Analysis
In the univariate analysis, 11 of 15 patient-related factors
and 8 of 15 procedure-related factors were found to be sta-
tistically significantly associated with an increased risk of
post-ERCP pancreatitis (Table 2). Technical factors that sig-
nificantly influenced the risk of pancreatitis included: minor
papilla sphincterotomy, major papilla pancreatic sphinctero-
tomy, moderate/difficult cannulation, performance of SOM,
pancreatic stent placement, minor papilla cannulation, and
therapeutic ERCP procedure. Trainee involvement and ≥2
pancreatic duct injection with contrast were almost significant
in the univariate analysis. Acinarization, precut sphinctero-
tomy, biliary sphincterotomy, biliary orifice balloon dilation,
and prior failed ERCP were not significant risk factors.
Significant patient-related risk factors by univariate anal-
ysis included: history of post-ERCP pancreatitis, pancreas
divisum, suspected SOD, recurrent idiopathic pancreatitis,
prior cholecystectomy, recurrent abdominal pain, age <60
yr, female sex, periampullary diverticulum, presence of com-
mon bile duct stone, and obstructive jaundice. Body mass
index, distal bile duct diameter, absence of chronic pancre-
atitis, and prednisone premedication were not significant risk
factors.
Multivariate Analysis
Only those risk factors that reached a p value cutoff 0.20 or
less were used to create the multivariate model. Table 3 shows
the results of the stepwise multiple logistic regression from
the pool of 21 potential risk factors in the univariate analy-
sis. Six risk factors were significant by multivariate analysis,
three were characteristics of the patients (suspected SOD,
younger age, prior history of post-ERCP pancreatitis), and
three were procedure-related (≥2 pancreatic duct injections,
minor papilla sphincterotomy, trainee involvement). There
was no evidence of multicollinearity issues or lack of fit. The
Hosmer-Lemeshow goodness of fit test was not significant
at the 0.05 significance level and the C-statistic was 0.692
(which nears 0.70, the value of acceptable predictive power).
Of the 11 cases with severe post-ERCP pancreatitis, the
risk factors are shown in Table 4. One patient had four
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Table 2. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis
Post-ERCP Pancreatitis Incidence (%)
Variables With Variable Without Variable p Value
Patient-related variables
Significant
History of previous post-ERCP pancreatitis 23/81 (28.4) 145/1034 (14.0) 0.0005
Pancreas divisum 30/123 (24.4) 138/992 (13.9) 0.002
Suspected sphincter of Oddi dysfunction 92/378 (24.3) 76/737 (10.3) <0.0001
Recurrent idiopathic pancreatitis 46/221 (20.8) 122/894 (13.6) 0.008
Prior cholecystectomy 64/327 (19.6) 104/788 (13.2) 0.007
Recurrent abdominal pain 120/656 (18.3) 48/459 (10.5) 0.0003
Age <60 yr 134/753 (17.8) 34/362 (9.4) 0.0002
Female sex 120/719 (16.7) 48/396 (12.0) 0.042
Periampullary diverticulum 10/119 (8.4) 158/994 (15.9) 0.03
Common bile duct stones 18/232 (7.8) 150/883 (17.0) 0.0005
Obstructive jaundice 10/145 (6.9) 158/970 (16.3) 0.003
Not significant
Body mass index <30 kg/m2 133/702 (18.9) 54/413 (13.1) 0.10
Prednisone premedication 92/555 (16.6) 76/560 (13.6) 0.19
Distal bile duct diameter <5 mm 47/302 (15.6) 99/688 (14.4) 0.63
Absence of chronic pancreatitis 137/923 (14.8) 31/192 (16.1) 0.28
Procedure-related variables
Significant
Minor papilla sphincterotomy 17/50 (34.0) 151/1065 (14.2) 0.0001
Major papilla pancreatic sphincterotomy 30/146 (20.6) 138/969 (14.2) 0.0485
Pancreatic sphincterotomy (major + minor) 47/196 (24.0) 121/919 (13.2) 0.002
Moderate/difficult cannulation 36/137 (26.3) 132/978 (13.5) <0.0001
Sphincter of Oddi manometry 94/395 (23.8) 74/720 (10.3) <0.0001
Pancreatic stent placement 49/218 (22.5) 119/897 (13.3) 0.0007
Minor papilla cannulation 31/146 (21.2) 137/969 (14.1) 0.03
Therapeutic ERCP procedure 105/579 (18.1) 63/536 (11.8) 0.003
Not significant
Acinarization 11/59 (18.6) 157/1056 (14.9) 0.43
Precut sphincterotomy 19/103 (18.4) 149/1012 (14.7) 0.31
Biliary sphincterotomy 74/451 (16.4) 94/664 (14.1) 0.30
Trainee involvement 100/588 (17.0) 68/524 (13.0) 0.06
≥2 pancreatic duct injections 103/613 (16.8) 65/502 (13.0) 0.07
Prior failed ERCP 22/156 (14.1) 146/959 (15.2) 0.72
Biliary orifice balloon dilatation 3/23 (13.0) 165/1092 (15.1) 0.78
independent risk factors for pancreatitis, four patients had
three, five patients had two, and one patient had one. Four of
these patients had successful pancreatic stent placement. The
average days of hospitalization were 18 days and one patient
died from the post-ERCP pancreatitis.
Table 3. Significant Risk Factors for Post-ERCP Pancreatitis by
Multivariate Analysis
Risk Odds 95% Confidence
Factors Ratio Interval p Value
Minor papilla 3.8 2.003–7.106 <0.0001
sphincterotomy
Suspected sphincter of 2.6 1.828–3.717 <0.0001
Oddi dysfunction
History of post-ERCP 2.0 1.186–3.448 0.01
pancreatitis
Age <60 yr 1.6 1.033–2.402 0.04
≥2 pancreatic 1.5 1.046–2.103 0.03
duct injections
Trainee involvement 1.5 1.029–2.057 0.03
DISCUSSION
The primary aim of this multicenter, randomized controlled
study was to evaluate the effect of corticosteroid on the in-
cidence of post-ERCP pancreatitis. Unfortunately, this study
and others found that prednisone did not reduce the incidence
or severity of post-ERCP pancreatitis (22). Identification of
patient- and procedure-related risk factors for post-ERCP
pancreatitis was prospectively evaluated as a secondary goal
of this study. This study suggests that the risk of pancreatitis
Table 4. Risk Factors of the 11 Cases with Severe Post-ERCP Pan-
creatitis
Risk Factors No. (Percentage)
Age <60 yr 8 (73%)
Trainee involvement 8 (73%)
Suspected sphincter of Oddi dysfunction 7 (63%)
≥2 pancreatic duct injections 7 (63%)
Minor papilla sphincterotomy 1 (9%)
History of post-ERCP pancreatitis 1 (9%)
Risk Factors for Post-ERCP Pancreatitis 143
is determined as much by patient characteristics as by en-
doscopic techniques or maneuvers. The overall post-ERCP
pancreatitis rate is 15.1%, which is higher than previous re-
ports and perhaps can be explained by a higher proportion of
patients with suspected SOD (33.9%) in our study popula-
tion. In previous prospective large-scale risk factor studies,
the reported pancreatitis rates ranged from 1.3% to 8.6%,
and the proportion of SOD patients was usually less than
10% (11–18).
The results of our study are in agreement with prior
prospective multivariate analysis studies with regard to sus-
pected SOD (11, 12, 19), younger age (11, 16, 18, 19), history
of post-ERCP pancreatitis (12–14), and pancreatic duct con-
trast injections (11, 12, 15, 18, 19) as independent predictors
for post-ERCP pancreatitis. Minor papilla sphincterotomy
was shown in the current study to be a significant risk fac-
tor by univariate and multivariate analysis, which was not
evaluated in the previous reports. Freeman et al. evaluated
pancreatic sphincterotomy and considered it as an indepen-
dent risk factor for pancreatitis, but they did not separate out
minor and major pancreatic sphincterotomy in that study (12).
There are conflicting data for the effect of endoscopic expe-
rience as a significant risk factor for post-ERCP pancreatitis
(11, 12, 17). Our results showed that trainee participation was
a significant risk factor by multivariate analysis.
One recent meta-analysis assessing risk factors for post-
ERCP pancreatitis revealed that suspected SOD, history of
post-ERCP pancreatitis, female sex, precut sphincterotomy,
and pancreatic contrast injections were independent predic-
tors for this complication (23). In a review that selectively
included full-length English language reports with multi-
variable analysis of the relationship between patient, proce-
dure, or operator factors and post-ERCP pancreatitis found
younger age, SOD, multiple pancreatic duct contrast injec-
tions, difficulty in cannulation, and precut sphincterotomy as
significant risk factors in more than one study (24). The fol-
lowing factors were analyzed but were not found to be signif-
icant for pancreatitis in any study: cholangitis, coagulopathy,
previous gastrectomy, history of jaundice, emergency proce-
dure, intramural injection, SOM, biliary drainage, length of
sphincterotomy, and bleeding during sphincterotomy.
The multivariate method has become the desired form of
data analysis, particularly for quantifying the independent
risk of an individual variable on the outcome. However, the
multivariate method is limited by the structure of the math-
ematical model and the coding of variables (25). Moreover,
adequate number of outcome events is needed to ensure ac-
curate p values and risk estimate. Therefore, some variables
may have minimal impact on the outcome despite achieving
statistical significance, whereas other variables that fail to
achieve the threshold of p < 0.05 may still have substantial
effect on the outcome (25). Because of the complex nature
of post-ERCP pancreatitis, there are numerous variables to
adjust for, many of which are closely interrelated and often
simultaneously present in the same case; it may be difficult
to precisely define risk factors with high degree of certainty.
For example, a young female with suspected SOD, who un-
dergoes ERCP and SOM with or without endoscopic sphinc-
terotomy that could involve a difficult cannulation along with
multiple pancreatic duct contrast injections is at high-risk for
post-ERCP pancreatitis. But what is the relative contribution
of each of these factors to pancreatitis may not be clear yet
since this scenario is very common among high-risk cases for
post-ERCP pancreatitis. It is also likely that other unknown
factors, for instance, at the cellular level (e.g., genetic sus-
ceptibility, hormonal or inflammatory mediators) may have a
significant role in such individuals indicating further consid-
eration.
Patients with suspected SOD carry a substantial risk for
pancreatitis after any type of ERCP, whether diagnostic,
manometric, or therapeutic (26). Our data show that a sus-
picion of SOD independently, nearly tripled the risk of post-
ERCP pancreatitis to a frequency (24%) that is comparable
with that found in other studies (9, 11, 12, 23). Contrary
to the widely held opinion that SOM is the cause for such
a high risk (27, 28), recent multivariate analyses show that
empirical biliary sphincterotomy or even diagnostic ERCP
in suspected SOD cases has similarly high risk, so that the
manometry appears to have been erroneously blamed by as-
sociation rather than being the cause (11, 12). Furthermore,
the widespread use of aspiration catheters for pancreatic duct
manometry is likely to have nearly eliminated any additional
risk of manometry from other ERCP instrumentation (29).
Placement of a prophylactic pancreatic stent in SOD pa-
tients has been shown to reduce the risk of post-ERCP pan-
creatitis (30, 31). The reason for the high susceptibility to
post-ERCP pancreatitis among patients with suspected SOD
remains unclear.
Mehta et al. conducted a study evaluating predictors of
post-ERCP complications in patients with suspected chole-
docholithiasis and found that absence of common bile duct
stones was an independent risk factor for post-ERCP pan-
creatitis (19). In this study, a younger patient (age <59 yr)
undergoing biliary sphincterotomy for suspected choledo-
cholithiasis without a stone in the bile duct had a 27% risk
of developing post-ERCP pancreatitis. Although the diag-
nosis of SOD was not considered in this study, the results
clearly showed the danger of performing ERCP to look for
bile duct stones in patients with recurrent postcholecystec-
tomy pain (in the absence of objective evidence for stones)
because there is generally a low probability of finding stones
in such patients and a high risk of causing pancreatitis. Mag-
netic resonance cholangiopancreatography and endoscopic
ultrasound can provide useful information in many of these
cases and are becoming widely available. These techniques
may be preferable to ERCP for patients with equivocal evi-
dence of biliary obstruction, especially those at high risk for
post-ERCP pancreatitis (12).
A history of previous post-ERCP pancreatitis was another
clinical risk factor for post-ERCP pancreatitis, and our find-
ings are consistent with several recent multivariate risk factor
studies (12–14). Our analysis showed that the risk in such
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patients was increased twofold (OR: 2.0). In the study by
Freeman et al., a history of previous post-ERCP pancreatitis
was found to be the most potent risk factor (OR: 5.4) (12).
Like other reports, a history of previous noniatrogenic pan-
creatitis is only a risk factor by univariate analysis, but not
by multivariate analysis (11, 12, 14).
Younger age was significant risk factor for pancreatitis in
our study and four other reports using multivariable analysis
(11, 16, 18, 19). However, a different age cutoff was used
in these studies with 60 yr in 3 and 70 yr in two studies,
respectively. The progressive decline in pancreatic exocrine
function with aging may protect older patients from pancre-
atic injury (32). Similarly, chronic pancreatitis was found to
provide some protection against ERCP-induced pancreatitis,
perhaps explained by atrophy and decreased enzymatic ac-
tivity (12). However, absence of chronic pancreatitis was not
a significant factor in the present study.
The finding of pancreatic contrast injections as an indepen-
dent risk factor for post-ERCP pancreatitis is consistent with
previous reports (11, 12, 14, 15, 18, 19). However, somewhat
different from other studies, our results showed that pancre-
atic contrast injections was barely significant (OR: 1.5), and a
difficult cannulation was not significant. A possible explana-
tion for these findings is that, unlike other similar studies, pro-
phylactic pancreatic stents were frequently used in our patient
group (about 20% of all ERCP) to reduce post-ERCP pancre-
atitis. There have been several prospective studies showing
that successful pancreatic stent placement might mitigate the
risk of post-ERCP pancreatitis (30, 31, 33). The higher post-
ERCP pancreatitis rates in this series (by univariate analysis)
in patients undergoing prophylactic pancreatic duct stenting
is almost certainly related to the fact that the stents were
placed in high-risk cases. Thus, the frequent use of prophy-
lactic pancreatic stents may somewhat modify the apparent
risk factors found in this study compared to traditional stud-
ies.
The mechanism of how contrast injection induces pancre-
atic ductal and acinar cell injury is not clear. Current evi-
dence does not support the notion that nonionic contrast is
more effective than conventional ionic contrast in prevent-
ing post-ERCP pancreatitis (1). The widely held concept is
that hydrostatic injury from overfilling of the pancreatic duct
with contrast material is a major cause of pancreatitis. Pre-
vious studies have demonstrated a ducto-interstitial-venous
pathway, and if enough radiographic contrast is injected into
the pancreatic duct, the collecting system of the kidney can
be seen during ERCP (34). Roszler et al. reported an inad-
vertent urogram during ERCP was followed by pancreatitis
in 45% of patients (35). The pathophysiologic basis for these
observations is related to the occurrence of ductal epithelial or
acinar injury, with resultant backflow of intraductal contents
into the interstitial space and venous circulation. However,
acinarization of the pancreas is probably less important than
has been previously believed. Most studies showed acinar-
ization of the pancreas was significant by univariate analysis
only (11, 16, 18). Like other recent studies, acinarization was
not a significant risk factor by univariate analysis in our series
(12, 14).
Difficult cannulation has been shown to be an indepen-
dent risk factor for pancreatitis and may occur without any
apparent pancreatic duct instrumentation (11–14). This sug-
gests that trauma to the papilla and pancreatic sphincter with
impaired pancreatic drainage may be important in the patho-
genesis of pancreatitis. Although there is an association with
the number of times the papilla was manipulated, the cutoff
numbers vary widely, with six attempts in two studies (11, 12)
and 20 attempts in one study (13). In the current study, how-
ever, moderate to difficult cannulation (>8 attempts) was only
significant in the univariate analysis and this was possibly due
to frequent placement of pancreatic stents mitigating this risk
factor as described above. The difficulty of cannulation is not
easily quantifiable and interactions with time for cannulation,
method of cannulating, and number of pancreatic duct injec-
tions may occur. Balloon dilation of the biliary sphincter to
extract bile duct stone was an independent factor for pan-
creatitis in a large multicenter study with a fourfold increase
in risk (12). Likewise, trauma to the pancreatic sphincter is
suspected to be the cause of pancreatitis. In our report, how-
ever, biliary orifice balloon dilatation was not found to be a
risk factor for post-ERCP pancreatitis. This may be due to
the infrequent performance of biliary orifice dilation in this
study.
Thermal injury of the papilla is exclusive to endoscopic
sphincterotomy. Edema produced by electrocautery is a well-
recognized consequence (36). It is hypothesized that swelling
around the pancreatic orifice may hinder the flow of pancre-
atic juice. Overall, performance of a standard biliary sphinc-
terotomy does not appear to add significant independent
risk of pancreatitis (12, 17, 20). On the contrary, pancreatic
sphincterotomy was found to be a significant risk of pancre-
atitis in a large multivariate analysis (12). Pancreatic duct
stenting appears to be beneficial in reducing the incidence
of pancreatitis after pancreatic sphincterotomy. Patel et al.
conducted a prospective, randomized, controlled study, and
the preliminary results showed that pancreatic duct stenting
after pancreatic sphincterotomy was associated with a lower
rate of pancreatitis but had not reached statistical signifi-
cance (37). Coagulation current causes more tissue injury and
edema than cutting current, and the use of pure cut current
has been shown to cause less pancreatitis than with blended
current sphincterotomy (38). In our series, we evaluated all
types of endoscopic sphincterotomy and found only minor
papilla sphincterotomy was an independent risk factor for
post-ERCP pancreatitis (OR: 3.8). Biliary sphincterotomy
was not a significant risk factor by univariate analysis. Pan-
creatic sphincterotomy of major papilla was significant only
by univariate but not by multivariate analysis. According to
our findings, pancreas divisum is not a risk factor unless mi-
nor papilla therapy is performed.
Precut papillotomy to gain access to the common bile duct
was not a risk factor in this study. However, like another sim-
ilar report (12), most of these procedures were performed by
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a few highly experienced endoscopists and often followed
or preceded by placement of a pancreatic stent, which has
been shown to reduce the risk of precutting (39). Increas-
ing numbers of reports from tertiary referral centers also
confirmed that complication rates were not different from
standard sphincterotomy (40). However, precutting was as-
sociated with a higher risk of pancreatitis in two other multi-
center studies involving endoscopists with varied experience
in ERCP (11, 16), and in the meta-analysis study (23). These
observations suggest that the risk of precut papillotomy is
highly operator dependent. Our data support the concept that
early use of precut by expert endoscopists might be prefer-
able to prolonged attempts at cannulation in patients at high
risk for pancreatitis (12, 17).
Trainee participation has been previously evaluated in one
large multicenter study and the result showed it was not a sig-
nificant risk factor (12). In another report by Vandervoort et
al., the complications of ERCP performed solely by attend-
ing physician were not significantly different from those per-
formed by fellows under the supervision of attending endo-
scopists, but detailed statistical data were not provided (13).
In our series, trainee participation did increase the risk by
multivariate analysis (OR: 1.5). The reason for this disagree-
ment was not clear. A similar discrepancy was also noted in
the evaluation of endoscopists’ case volume as a risk factor
for post-ERCP pancreatitis. Some series reported low case
volume was not significant in the multivariate analysis (12,
15), while others considered it as independent risk factor of
pancreatitis (17, 18). Low case volume was also an inde-
pendent risk factor for postsphincterotomy bleeding in two
large multicenter series (11, 12). In the prospective multicen-
ter study by Freeman et al., sphincterotomy-induced com-
plications were noted more frequently at university-affiliated
referral centers than private practices, which the authors at-
tributed to different case mix (11). All of these observations
suggest that case mix is at least as important as expertise in
determining risk of post-ERCP pancreatitis.
There is an escalating risk of post-ERCP pancreatitis in
patients with multiple risk factors (12, 14). In the report by
Freeman et al., a woman with normal serum bilirubin, easy
cannulation, and a bile duct stone had about a 5% chance of
post-ERCP pancreatitis. If an even moderately difficult can-
nulation was encountered, the risk rose to more than 16%.
If such a patient also had suspected SOD and had a difficult
cannulation, the risk of pancreatitis rose to more than 40%
(12). Friedland et al. designed a bedside scoring system for
the risk of post-ERCP pancreatitis based on the results of
multivariate analysis (14). Independent risk factors included
in the scoring system were new pain during ERCP, pancreatic
ductal contrast injection, a prior history of post-ERCP pan-
creatitis, and difficult cannulation. The results showed that
cases scoring 4 or fewer points (the low-risk group) had a
2% risk of post-ERCP pancreatitis, cases scoring between
5 and 8 points (the medium-risk group) had a 7% risk, and
cases scoring more than 8 (the high-risk group) had a 28%
risk.
Pharmacological methods to prevent post-ERCP pancre-
atitis have been studied for many years. Most drugs appear
promising in initial randomized single-center trials; however,
conflicting results are often obtained from larger, multicenter
studies. Octreotide, steroids, and interleukin-10 are typical
examples. From the meta-analysis report by Andriulli et al.,
somatostatin (an antisecretory agent) and gabexate mesilate
(a protease inhibitor) are two effective prophylactic drugs for
preventing post-ERCP pancreatitis (41). Neither drug is avail-
able in the United States. The number of patients that need to
be treated with both drugs to prevent a single case of pancre-
atitis is 13–27. One recent report showed that a single dose of
diclofenac (a nonsteroidal antiinflammatory agent, NSAID)
suppository helped to reduce the incidence of post-ERCP
pancreatitis (42). NSAIDs can inhibit the early inflammatory
cascade involving phospholipase-A2, prostaglandins, or en-
dothelial neutrophil attachment during acute pancreatitis. It
should be appreciated that this is only a single-center study
and diclofenac was not effective in the subgroup of patients
with SOD, the very group of patients that are at greatest risk.
A larger multicenter study is needed to confirm the protective
role of NSAIDs.
In conclusion, multivariate analysis indicates that patient-
related risk factors are as important as technical ones. Until
effective, safe, and low-cost prophylactic drugs are defini-
tively identified and made available, selective use in high-risk
groups may be warranted. Unfortunately, such a drug is not
available in the United States. Risk stratification will allow
endoscopists to better identify patients who are at significant
risk and permit detailed informed consent as well as possibly
defer examinations in the highest-risk groups. Appropriate
technical “prophylaxis” during ERCP, such as pancreatic duc-
tal stenting, should also be carefully considered in high-risk
patients to prevent the development of pancreatitis.
Appendix
Other contributing authors: Klaus Gottlieb, MD, Indiana Uni-
versity Medical Center, Indianapolis, Indiana; Kevin Block,
MD, Mark Reichelderfer, MD, University of Wisconsin,
Madison, Wisconsin; Grace Elta, MD, William D. Chey,
MD, University of Michigan, Ann Arbor, Michigan; Oliver
Cass, MD, Hennepin County Medical Center, Minneapo-
lis, Minnesota; Marc Catalano, MD, Michael Schmalz, MD,
Daniel Geenen, MD, GI Consultants Ltd., Milwaukee, Wis-
consin; Christopher Rall, MD, Marshfield Clinic, Marsh-
field, Wisconsin; David Carron, MD, Milwaukee GI Spe-
cialists, Milwaukee, Wisconsin; John Johanson, MD, Roger
Greenlaw, MD, Mark Shiels, MD, Rockford Gastroenterol-
ogy Associates, Ltd., Rockford, Illinois; Adam Slivka, MD,
University of Pittsburgh, Pittsburgh, Pennsylvania; Anthony
Bohorfoush, MD, Reza Shaker, MD, Medical College of Wis-
consin, Milwaukee, Wisconsin; Hitesh Chokshi, MD, David
Walden, MD, Washington University, St. Louis, Missouri;
Raja Kaikaus, MD, University of Louisville, Louisville,
Kentucky.
146 Cheng et al.
ACKNOWLEDGMENT
This study was supported by AGA Foundation Smith Kline
Beecham Clinical Research Award.
Reprint requests and correspondence: Stuart Sherman, M.D.,
Professor of Medicine and Radiology, Indiana University Medical
Center, 550 N University Blvd, Suite 4100, Indianapolis, IN 46202.
Received August 11, 2004; accepted August 9, 2005.
REFERENCES
1. Gottlieb K, Sherman S. ERCP and endoscopic biliary
sphincterotomy-induced pancreatitis. Gastrointest Endosc
Clin N Am 1998;8:87–114.
2. Freeman ML. Adverse outcomes of ERCP. Gastrointest En-
dosc 2002;56(Suppl):S273–82.
3. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphinc-
terotomy complications and their management: An attempt
at consensus. Gastrointest Endosc 1991;37:383–93.
4. Huibregtse K. Complications of endoscopic sphincterotomy
and their prevention. N Engl J Med 1996;335:961–2.
5. Hofbauer B, Saluja AK, Lerch MM, et al. Intra-acinar cell
activation of trypsinogen during cerulean-induced pancre-
atitis in rats. Am J Physiol 1998;275:G352–62.
6. Sherman S, Ruffolo TA, Hawes RH, et al. Complications of
endoscopic sphincterotomy: A prospective series with em-
phasis on the increased risk associated with sphincter of
Oddi dysfunction and nondilated bile ducts. Gastroenterol-
ogy 1991;101:1068–75.
7. Wilson MS, Tweedle DEF, Martin DF. Common bile duct
diameter and complications of endoscopic sphincterotomy.
Br J Surg 1992;79:1346–7.
8. Chen YK, Foliente RL, Santoro MJ, et al. Endoscopic
sphincterotomy-induced pancreatitis: Increased risk asso-
ciated with nondilated bile ducts and sphincter of Oddi dys-
function. Am J Gastroenterol 1994;89:327–33.
9. Tarnasky P, Cunningham J, Cotton P, et al. Pancreatic
sphincter hypertension increases the risk of post-ERCP pan-
creatitis. Endoscopy 1997;29:252–7.
10. Johnson GK, Geenen JE, Johason JF, et al. Evaluation of
post-ERCP pancreatitis: Potential causes noted during con-
trolled study of differing contrast media. Gastrointest En-
dosc 1997;46:217–22.
11. Freeman ML, Nelson DB, Sherman S, et al. Complica-
tions of endoscopic biliary sphincterotomy. N Engl J Med
1996;335:909–18.
12. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for
post-ERCP pancreatitis: A prospective, multicenter study.
Gastrointest Endosc 2001;54:425–34.
13. Vandervoort J, Soetikno RM, Tham TCK, et al. Risk factors
for complications after performance of ERCP. Gastrointest
Endosc 2002;56:652–6.
14. Friedland S, Soetikno RM, Vandervoort J, et al. Bedside
scoring system to predict the risk of developing pancreatitis
following ERCP. Endoscopy 2002;34:483–8.
15. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somato-
statin administration before ERCP in patients at high risk for
post-ERCP pancreatitis: A multicenter, placebo-controlled,
randomized clinical trial. Gastrointest Endosc 2002;56:488–
95.
16. Masci E, Toti G, Mariani A, et al. Complications of diagnos-
tic and therapeutic ERCP: A prospective multicenter study.
Am J Gastroenterol 2001;96:417–23.
17. Rabenstein T, Schneider HT, Bulling D, et al. Analysis of
the risk factors associated with endoscopic sphincterotomy
techniques: Preliminary results of a prospective study, with
emphasis on the reduced risk of acute pancreatitis with low-
dose anticoagulation treatment. Endoscopy 2000;32:10–9.
18. Loperfido S, Angelini G, Benedetti G, et al. Major early
complications from diagnostic and therapeutic ERCP:
A prospective multicenter study. Gastrointest Endosc
1998;48:1–10.
19. Mehta SN, Pavone E, Barkun JS, et al. Predictors of post-
ERCP complications in patients with suspected choledo-
cholithiasis. Endoscopy 1998;30:457–63.
20. Maldonado ME, Brady PG, Mamel JJ, et al. Incidence
of pancreatitis in patients undergoing sphincter of Oddi
manometry. Am J Gastroenterol 1999;94:387–90.
21. Sarner M, Cotton PB. Classification of pancreatitis. Gut
1984;25:756–9.
22. Sherman S, Blaut U, Watkins JL, et al. Does prophylactic
administration of corticosteroid reduce the risk and sever-
ity of post-ERCP pancreatitis: A randomized, prospective,
multicenter study. Gastrointest Endosc 2003;58:23–9.
23. Masci E, Mariani A, Curioni S, et al. Risk factors for pan-
creatitis following endoscopic retrograde cholangiopancre-
atography: A meta-analysis. Endoscopy 2003;35:830–4.
24. Aronson N, Flamm CR, Bohn RL, et al. Evidence-based
assessment: patient, procedure, or operator factors as-
sociated with ERCP complications. Gastrointest Endosc
2002;56(Suppl):S294–302.
25. Concato J, Feinstein AR, Holford TR. The risk of de-
termining risk with multivariate modes. Ann Intern Med
1993;118:201–10.
26. Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi
dysfunction: Pancreatobiliary sphincterotomy with pancre-
atic stent placement has a lower rate of pancreatitis than
biliary sphincterotomy alone. Endoscopy 2002;34:280–5.
27. Hogan WJ. Stenting the pancreas: Is this the solution to post-
ERCP pancreatitis? Gastroenterology 1998;115:1591–4.
28. Rolny P, Anderberg B, Ishe I, et al. Pancreatitis after sphinc-
ter of Oddi manometry. Gut 1990;31:821–4.
29. Sherman S, Troiano FP, Hawes RH, et al. Sphincter of
Oddi manometry: Decreased risk of clinical pancreatitis
with use of a modified aspirating catheter. Gastrointest En-
dosc 1990;31:821–4.
30. Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic
stenting prevents pancreatitis after biliary sphincterotomy in
patients with sphincter of Oddi dysfunction. Gastroenterol-
ogy 1998;115:1518–24.
31. Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic
duct stent prevent post-ERCP pancreatitis? A prospective
randomized study. Gastrointest Endosc 2003;57:291–4.
32. Laugier R, Bernard JP, Berthezene P, et al. Changes in pan-
creatic exocrine secretion with age: Pancreatic exocrine se-
cretion does decrease in the elderly. Digestion 1991;50:202–
11.
33. Freeman ML, Overby C, Qi D. Pancreatic stent insertion:
Consequences of failure and results of a modified technique
to maximize success. Gastrointest Endosc 2004;59:8–14.
34. Waldron RL, Luse SA, Wollowick HE, et al. Demonstra-
tion of a retrograde pancreatic pathway: Correlation of
roentgenographic and electron microscopic studies. Am J
Roentgenol Radium Ther Nucl Med 1971;111:695–9.
35. Roszler MH, Campbell WL. Post-ERCP pancreatitis: Asso-
ciation with urographic visualization during ERCP. Radiol-
ogy 1985;157:595–8.
36. Sivak MV. Endoscopic management of bile duct stone. Am
J Surg 1989;158:228–40.
37. Patel R, Tarnasky PR, Hennessy WS, et al. Does stent-
ing after pancreatic sphincterotomy reduce post-ERCP
Risk Factors for Post-ERCP Pancreatitis 147
pancreatitis in patients with prior biliary sphincterotomy?:
Preliminary results of a prospective randomized trial [ab-
stract]. Gastrointest Endosc 1999;49:AB80.
38. Elta GH, Barnett JL, Wille RT, et al. Pure cut elec-
trocautery current for sphincterotomy causes less post-
procedure pancreatitis than blended current. Gastrointest
Endosc 1998;47:149–53.
39. Sherman S, Hawes R, Earle D, et al. Does leaving a main
pancreatic stent in place reduce the incidence of biliary
precut-induced pancreatitis? [abstract]. Gastrointest Endosc
1994;40:AB124.
40. Slot WB, Schoeman MN, Disario JA, et al. Needle-
knife sphincterotomy as a precut procedure: A retrospec-
tive evaluation of efficacy and complications. Endoscopy
1996:28:334–9.
41. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treat-
ment can prevent pancreatic injury after ERCP: A meta-
analysis. Gastrointest Endosc 2000;51:1–7.
42. Murray B, Carter C, Imrie C, et al. Diclofenac re-
duces the incidence of acute pancreatitis after endo-
scopic retrograde cholangiopancreatography. Gastroenterol-
ogy 2003;124:1786–91.
